Acute Myeloblastic Leukemia Type 1

Search Trials
Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission
Status:
Terminated
Last Changed:
Apr 4, 2017
First Changed:
Apr 11, 2011
Disease(s):
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Intervention(s):
bortezomib
Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Terminated
Last Changed:
Feb 7, 2017
First Changed:
Jan 1, 1970
Disease(s):
Adult Acute Megakaryoblastic Leukemia (M7)
Intervention(s):
cyclosporinepravastatin sodiummitoxantrone hydrochlorideetoposidebone marrow aspiration
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Status:
Active, not recruiting
Last Changed:
Jan 1, 1970
First Changed:
Dec 3, 2014
Disease(s):
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Intervention(s):
clofarabinedaunorubicin hydrochlorideclinical observationcytarabinedecitabinelaboratory biomarker analysisquality-of-life assessmentquestionnaire administration
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Withdrawn
Last Changed:
Jan 1, 1970
First Changed:
Jan 1, 1970
Disease(s):
Adult Acute Megakaryoblastic Leukemia (M7)
Intervention(s):
arsenic trioxidelaboratory biomarker analysis
Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Status:
Completed
Last Changed:
Jan 1, 1970
First Changed:
Jan 1, 1970
Disease(s):
Adult Acute Megakaryoblastic Leukemia (M7)
Intervention(s):
pravastatin sodiumidarubicincytarabinelaboratory biomarker analysis

Connect. Empower. Inspire.